As geopolitical changes have made working with China more risky than before, European firms have backed away from infrastructure projects linked with the Belt and Road Initiative.
An international research team led by the Hong Kong University of Science and Technology (HKUST) has reportedly developed a groundbreaking blood test for the early detection of Alzheimer’s disease (AD) and mild cognitive impairment (MCI) with remarkable accuracy rates. Key features: Unlike current blood tests that focus on a single biomarker to determine brain pathology, the new test measures the levels of 21 proteins in multiple AD-associated biological pathways, allowing for a more accurate assessment and monitoring of disease progression.
Hong Kong-developed blood test for identifying dementia in its early stages, when it is easier to treat, is another measure of city’s progress in the biotech arena.